TUMORGPLAT · Making patient-derived tumor organoids a reliable cancer therapy testing platform
Horizon Europe — Marie Skłodowska-Curie Actions
- Duration
- 2026-01-01 → 2029-12-31
- EU contribution
- €245,490
- Participants
- 6
- Scheme
- HORIZON-TMA-MSCA-SE
Lines connect the coordinator with its partners.
Project objective
We aim to establish a European network of experts in non-animal preclinical models to develop the next generation of patient-derived tumor organoids (PDTOs) for both solid and hematological cancers. To this end, we have selected non-small cell lung cancer as a model, given its high incidence, and chronic lymphocytic leukemia and follicular lymphoma as representative B cell malignancies.These PDTOs will incorporate a novel, tissue-specific artificial extracellular matrix, created using tailored 3D biohybrid hydrogels designed to mimic the human tumor microenvironment (TME). By integrating patient-derived tumor, immune, and stromal cells, the PDTOs will closely replicate the complexity of the original tumors, which will be evaluated using a multi-technique approach, including comprehensive omics characterization.Our ultimate goal is to establish a robust platform for testing innovative therapies—particularly radiotherapy and immunotherapy—within the framework of personalized medicine. Specifically, we will focus on adoptive cell therapies using CAR T and NK cells, neutron capture (radio)therapy, and their combination.
Original text from CORDIS.
Participants
- AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS · MadridCoordinatorSpain
- FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI · MilanItaly
- FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER · BarcelonaSpain
- IMMUNDNZ LIMITED · SittingbourneUnited Kingdom
- UNIVERSITA DEGLI STUDI DI PAVIA · PaviaItaly
- UNIVERSITAT POLITECNICA DE VALENCIA · ValenciaSpain
Links
Data: CORDIS, © European Union